GlassScriptPhysician profile
Sirisha Chalasani
NPI 1508849068
$2,967.85
in general payments reported to CMS, 2019-2025
24 companies · $1,751 in 2025
The $1,751 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $169 · 2021: $33.89 · 2022: $14.14 · 2023: $281 · 2024: $366 · 2025: $1,751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,398.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $533.55 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $517.89 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $425.03 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astellas Pharma US INC | $229.74 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.23 | 2019-2025 | Jardiance |
| Amgen INC. | $173.61 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $158.37 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $110.91 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $106.00 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $89.86 | 2024-2025 | |
| Abbvie INC. | $85.42 | 2025 | |
| Novartis Pharmaceuticals Corporation | $47.29 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $44.17 | 2019-2024 | Xarelto |
| Paratek Pharmaceuticals, INC. | $40.33 | 2025 | Nuzyra, Xhance |
| Sumitomo Pharma America, INC. | $36.29 | 2024-2025 | Gemtesa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $35.93 | 2019 | |
| Merck Sharp & Dohme LLC | $33.48 | 2020-2025 | Verquvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.06 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $21.00 | 2024 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $15.63 | 2019 | |
| Boston Scientific Corporation | $15.58 | 2019 | |
| Nevro Corp. | $15.53 | 2024 | Senza |
| Otsuka America Pharmaceutical, INC. | $14.64 | 2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sirisha Chalasani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.